Subscribe to TheStreet's free daily newsletter 💰💵 That is why the market saw AbbVie make a number of acquisitions to expand ...

The stock's fall snapped a two-day winning streak.

ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

AbbVie ABBV announced strong fourth-quarter 2024 results last week, beating estimates for both earnings and sales. While earnings of $2.16 per share declined around 22% year over year, sales rose 6.1% ...

AbbVie (NYSE:ABBV – Get Free Report) had its target price raised by equities research analysts at Wells Fargo & Company from $195.00 to $210.00 in a note issued to investors on Monday,Benzinga reports ...

AbbVie (NYSE:ABBV – Get Free Report) had its price target lifted by equities researchers at UBS Group from $181.00 to $190.00 in a note issued to investors on Monday,Benzinga reports. The brokerage ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

AbbVie (ABBV) stock rallied today after the biopharmaceutical company posted its Q4 2024 earnings report. The good news ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on AbbVie (ABBV – Research Report) on January 31. The company’s shares opened ...

Humira's reign has come to an end, but it's not the end for AbbVie. AbbVie’s Humira was the biopharmaceutical company's top-selling drug for two decades, generating $21 billion of revenue in ...